TEV-48574 is a medication being studied for its effects on patients with moderate to severe ulcerative colitis or Crohn’s disease. It is administered through a subcutaneous injection every four weeks. The study aims to evaluate how well this medication helps maintain clinical remission in ulcerative colitis and endoscopic response in Crohn’s disease over a long-term period.

Ulcerative Colitis – Ulcerative colitis is a chronic inflammatory condition affecting the colon and rectum. It is characterized by inflammation and ulceration of the innermost lining of the colon, leading to symptoms such as abdominal pain, diarrhea, and rectal bleeding. The disease often progresses with periods of flare-ups and remissions. During flare-ups, symptoms can become more severe, while remissions may bring relief. The exact cause of ulcerative colitis is unknown, but it is believed to involve an abnormal immune response. The condition can significantly impact daily life and requires ongoing management.

Crohn’s Disease – Crohn’s disease is a chronic inflammatory bowel disease that can affect any part of the gastrointestinal tract, from the mouth to the anus. It is characterized by inflammation that can penetrate deep into the layers of the bowel tissue, leading to symptoms such as abdominal pain, diarrhea, weight loss, and fatigue. The disease often progresses with alternating periods of active symptoms and remission. The inflammation can cause complications such as strictures, fistulas, and malnutrition. The exact cause of Crohn’s disease is not fully understood, but it involves a combination of genetic, environmental, and immune factors. Managing the disease requires a comprehensive approach to control symptoms and prevent complications.